Renaissance Technologies LLC Invests $3.17 Million in Establishment Labs Holdings Inc. $ESTA

Renaissance Technologies LLC purchased a new position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 55,800 shares of the company’s stock, valued at approximately $3,168,000. Renaissance Technologies LLC owned approximately 0.19% of Establishment Labs as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Simplify Asset Management Inc. boosted its stake in Establishment Labs by 92.1% during the 4th quarter. Simplify Asset Management Inc. now owns 72,894 shares of the company’s stock worth $5,313,000 after purchasing an additional 34,946 shares during the last quarter. Sigma Planning Corp grew its holdings in shares of Establishment Labs by 325.5% during the first quarter. Sigma Planning Corp now owns 20,424 shares of the company’s stock worth $1,160,000 after buying an additional 15,624 shares in the last quarter. SG Americas Securities LLC raised its position in shares of Establishment Labs by 134.3% in the first quarter. SG Americas Securities LLC now owns 37,928 shares of the company’s stock valued at $2,154,000 after buying an additional 21,742 shares during the last quarter. AlTi Global Inc. purchased a new position in shares of Establishment Labs in the first quarter worth about $842,000. Finally, Sofinnova Investments Inc. lifted its stake in shares of Establishment Labs by 163.0% in the fourth quarter. Sofinnova Investments Inc. now owns 28,366 shares of the company’s stock worth $2,067,000 after buying an additional 17,579 shares in the last quarter. 72.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ESTA has been the topic of a number of recent research reports. Citigroup boosted their price target on shares of Establishment Labs from $76.00 to $92.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Needham & Company LLC raised their target price on shares of Establishment Labs from $86.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday. BTIG Research boosted their target price on Establishment Labs from $96.00 to $103.00 and gave the stock a “buy” rating in a report on Thursday. Canaccord Genuity Group set a $105.00 price target on Establishment Labs in a research report on Thursday. Finally, TD Cowen increased their price target on Establishment Labs from $95.00 to $117.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $100.25.

Establishment Labs Trading Down 2.1%

Shares of ESTA stock opened at $77.42 on Friday. The company has a current ratio of 2.96, a quick ratio of 1.91 and a debt-to-equity ratio of 16.82. Establishment Labs Holdings Inc. has a twelve month low of $33.35 and a twelve month high of $97.59. The company’s 50-day moving average price is $86.43 and its 200-day moving average price is $74.25. The stock has a market cap of $2.28 billion, a price-to-earnings ratio of -59.10 and a beta of 1.07.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Establishment Labs had a negative return on equity of 205.79% and a negative net margin of 15.82%.The firm had revenue of $67.54 million for the quarter, compared to analyst estimates of $65.79 million. During the same quarter in the previous year, the business posted ($0.57) earnings per share. Establishment Labs’s revenue for the quarter was up 31.7% on a year-over-year basis. As a group, equities analysts predict that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current year.

Establishment Labs News Roundup

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: JPMorgan raised its price target on Establishment Labs from $84 to $95 and maintained an Overweight rating, implying substantial upside from the current trading level. Benzinga analyst report
• Positive Sentiment: BTIG increased its price target from $96 to $103 and reiterated a Buy rating, while Needham lifted its target from $86 to $95 and also maintained a Buy rating. These revisions suggest analysts remain optimistic about the company’s growth prospects. The Fly analyst report
• Positive Sentiment: Establishment Labs reported quarterly revenue of $67.54 million, exceeding the $65.79 million analyst estimate and increasing 31.7% year over year. The company also projected 2026 revenue of $269 million to $271 million, above the $267.5 million consensus estimate. Zacks quarterly results report
• Neutral Sentiment: Management indicated that minimally invasive procedures now account for approximately 15% of sales, highlighting potential for longer-term market expansion, but investors may remain focused on the company’s path to profitability. Seeking Alpha revenue outlook report
• Negative Sentiment: The company reported a second-quarter loss of $0.39 per share, wider than the $0.34 expected loss, though the result improved from a $0.57 loss in the year-ago quarter. The earnings miss, continued negative margins, and lack of profitability are likely weighing on the shares. MarketBeat earnings report

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.